Physician profile
Chainaronk Limanon
NPI 1861597528
$1,687.30
in general payments reported to CMS, 2019-2025
23 companies · $416 in 2025
The $416 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.40 · 2020: $102 · 2021: $162 · 2022: $420 · 2023: $254 · 2024: $248 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $230.55 | 2019-2025 | Wegovy |
| Hologic Sales and Service, LLC | $181.16 | 2021-2025 | Aptima |
| Exact Sciences Corporation | $152.23 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $115.57 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $113.77 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.89 | 2020-2022 | |
| Abbvie INC. | $101.17 | 2020-2022 | |
| Gilead Sciences, INC. | $93.94 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.40 | 2022 | |
| Astellas Pharma US INC | $73.56 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $63.59 | 2021-2023 | Arexvy, Bexsero, Shingrix |
| Alk-Abello, INC | $55.15 | 2024-2025 | Grastek, Odactra, Neffy |
| Merck Sharp & Dohme LLC | $45.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.49 | 2024 | Xifaxan |
| Pfizer INC. | $39.49 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $30.96 | 2021 | |
| Therapeuticsmd, INC. | $28.31 | 2022 | |
| Qiagen, LLC | $27.47 | 2024 | |
| Dexcom, INC. | $25.90 | 2025 | Dexcom G6 Transmitter |
| Vbi Vaccine (Delaware) INC. | $25.89 | 2022 | |
| Phadia US INC. | $19.95 | 2024 | Immunocap |
| Edwards Lifesciences Corporation | $19.75 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $17.88 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chainaronk Limanon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.